Stealth PEG-PHDCA niosomes: Effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity

Journal of Pharmaceutical Sciences

Volumn 95, Issue 9, 2006, Pages 1873-1887

  Shi, Bin ^a   Fang, Chao ^a   Pei, Yuanying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antitumor effects; Hydroxycamptothecin; Niosomes; Pharmacokenitics; Poly (methoxy polyethyleneglycol cyanoacrylate co n hexadecyl cyanoacrylate)

Indexed keywords

CAMPTOTHECIN DERIVATIVE; HYDROXYCAMPTOTHECIN; LACTONE; MACROGOL; MACROGOL 10000; MACROGOL 2000; MACROGOL 5000; METHOXYPOLYETHYLENEGLYCOL CYANOACRYLATE CO N HEXADECYL CYANOACRYLATE; NIOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; RAT; SURFACE PROPERTY; ZETA POTENTIAL;

EID: 33748933568     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20491     Document Type: Article

References (30)

1. Uchegbu IF, Vyas SP. 1998. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172:33-70.
2. Hao Y, Zhao F, Li N, Yang Y, Li K. 2002. Studies on a high encapsulation of colchicines by a niosomes system. Int J Pharm 244:73-80.
3. Florence AT. 1993. New drug delivery systems chemistry and industry. 20 December, 1000-1004.
4. Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT. 1996. The activity of doxorubicin niosomes against an ovarian-cancer cell-line and in-vivo mouse-tumor models. J Drug Target 3:399-409.
5. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D. 1997a. Complement consumtion by poly (ethylene glycol) in different conformations chemically coupled to poly (isobutyl 2-cyanoacrylate) nanoparticles. Life Sci 61:749-761.
6. Peracchia MT, Desmaele D, Couvreur P, d'Angelo J. 1997b. Synthesis of a novel (PEG cyanoacrylate-co-alkyl cyanoacrylate)amphiphilic copolymer for nanoparticle technology. Macromolecules 30:846-851.
7. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaele D, dAngelo J, Muller RH, Couvereur P. 1999. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 20: 1269-1275.
8. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Zhou JJ, Gao XJ. 2001. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers. J Control Rel 71:287-296.
9. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Zhou JJ, Gao XJ, Zhu JH. 2001. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and antitumor effects. Biol Pharm Bull 24:662-665.
10. Li YF, Zhang RW. 1996. Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues. J Chromatography B 686: 257-265.
11. Hatefi A, Amsden B. 2002. Camptothecin delivery methods. Pharm Res 19:1389-1399.
12. Rowinsky E, Grochow L, Hendricks CB, Ettinger D, Forastier AA, Horowitz LA, Donehower DC. 1992. Phase I and pharmacologic study of Topotecan, a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656.
13. Sadzuka Y, Nakade A, Hirama R, Miyagishima A, Nozawa Y, Hirota S, Sonobe T. 2002. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. Int J Pharm 238:171-180.
14. Shenderova A, Burke TG, Schwendeman SP. 1997. Stabilization of 10-hydroxycamptothecin in poly (lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 14:1406-1414.
15. Mosqueira VCF, Legrand P, Morgat JL, Vert M, Mysiakine E, Gref R, Devissaguet JP, Barratt G. 2001. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and surface density. Pharm Res 18:1411-1419.
16. Burke TG, Staubus AE, Mishra AK. 1992. Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 114:8318-8319.
17. Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. 1997. Formulation study for the anti-tumor drug camptothecin: liposomes, micelle solutions and a microemulsion. Int J Pharm 159:95-103.
18. Zhang LY, Hu Y, Jiang X, Yang CZ, Lu W, Yang YH. 2004. Camptothecin derivative-loaded poly (caprolactone-co-lactide)-b-PEG-b-poly (caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Contr Rel 96:135-148.
19. Sadzuka Y, Nakade A, Tsuruda T, Sonobe T. 2003. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin. J Control Rel 91:271-280.
20. Needham D, Stoicheva N, Zhelev DV. 1997. Exchange of monooleoylphosphtidycholine as monomer and micelle with membranes containing polyethylene glycol-lipid. Biophys J 73:2615-2629.
21. Torchilin VP. 2001. Structure and design of polymeric surfactant-based drug delivery systems. J Control Rel 73:137-172.
22. Peracchia MT, Vauthier C, Desmaele D. 1998. Peglated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 15: 550-556.
23. Shi B, Fang C, Pei YY. 2005. Biodegradable poly (methoxypolyethyleneglycol cyanoacrylate-co-hexadecyl cyanoacrylate)(PEG-PHDCA) graft copolymers: characterization and their use as drug carriers for a controlled delivery system. Coll Surf B:Biointerf, In review.
24. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation halt-life in vivo. Biochim Biophys Acta 1066:29-36.
25. Woodle MC. 1993. Surface-modified liposomes-assessment and characterization for increased stability and prolonged blood-circulation. Chem Phys Lipids 64:249-262.
26. Woodle MC, Matthay KK, Newman M. 1992. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochem Biophys Acta 1105:193-200.
27. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. 2000. Stealth corona-core nanoparticles surface modified by polyethylene glycol: influences of the corona PEG chain length and surface density and of the core composition on phagocytic uptake and plasma protein adsorption. Coll Surf B:Biointerf 18:301-313.
28. Bazile D, Prud'Homme C, Bassoulet MT, Marlard M, Spenlehauer G, Veillard M. 1995. Stealth PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84:493-498.
29. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. 1995. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215-233.
30. Jang SH, Wienties MG, Lu D, Au JL. 2003. Durg delivery and transport to solid tumors. Pharm Res 20:1337-1350.